within Pharmacolibrary.Drugs.ATC.J;

model J06BB05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 5.833333333333333e-08,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BB05</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rabies immunoglobulin (RIG) is a human or equine-derived immunoglobulin preparation used for passive immunization following suspected exposure to rabies virus, typically as part of post-exposure prophylaxis, in conjunction with rabies vaccination. It is indicated for individuals who have not been previously immunized against rabies and is administered to confer immediate passive immunity while the patient mounts an active immune response to the vaccine. RIG is an approved and essential component in rabies prevention protocols worldwide.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics in healthy adults following intramuscular administration. No direct comprehensive PK modeling study on rabies immunoglobulin in literature; values estimated based on available product information and class-level data (human immunoglobulins).</p><h4>References</h4><ol><li><p>Lang, J, et al., &amp; Sabchareon, A (1998). Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. <i>Acta tropica</i> 70(3) 317–333. DOI:<a href=&quot;https://doi.org/10.1016/s0001-706x(98)00038-2&quot;>10.1016/s0001-706x(98)00038-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9777717/&quot;>https://pubmed.ncbi.nlm.nih.gov/9777717</a></p></li><li><p>Arya, JM, et al., &amp; Prausnitz, MR (2016). Rabies vaccination in dogs using a dissolving microneedle patch. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 239 19–26. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2016.08.012&quot;>10.1016/j.jconrel.2016.08.012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27524283/&quot;>https://pubmed.ncbi.nlm.nih.gov/27524283</a></p></li><li><p>McClain, JB, et al., &amp; Tsao, E (2021). Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis. <i>Clinical pharmacology in drug development</i> 10(7) 807–817. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.917&quot;>10.1002/cpdd.917</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33493368/&quot;>https://pubmed.ncbi.nlm.nih.gov/33493368</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BB05;
